/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

M

Mathilde Morisseau

Institut Claudius Regaud(FR)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

18

Papers

70

Citations

3

h-index

2

i10-index

Mathilde Morisseau is an academic researcher from Institut Claudius Regaud. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & HER2/EGFR in Cancer Research & Cancer Treatment and Pharmacology. The author has an h-index of 3, co-authored 16 publications.

Research Topics

Cancer Immunotherapy and Biomarkers HER2/EGFR in Cancer Research Cancer Treatment and Pharmacology Head and Neck Cancer Studies Immunotherapy and Immune Responses

Papers by this author

works

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer

2024 · British Journal of Cancer · 42 citations

https://doi.org/10.1038/s41416-024-02766-9

François Poumeaud Mathilde Morisseau Luc Cabel A. Gonçalves

849: Relapse Risk stratification in pediatric ependymoma patients using clinical data and radiomics

2024 · Radiotherapy and Oncology · 0 citations

https://doi.org/10.1016/s0167-8140(24)01371-9

Fatima Tensaouti Nhi Blanchard Mathilde Morisseau Stéphanie Bolle

3282 Pediatric localized intracranial ependymoma: survival, prognostic factors in a French multicentric retrospective study from 2000 to 2021 (NCT05151718)

2025 · Radiotherapy and Oncology · 0 citations

https://doi.org/10.1016/s0167-8140(25)01600-7

Alexis Marguerit Fatima Tensaouti Mathilde Morisseau Stéphanie Bolle

3629 Tolerance of adjuvant radiotherapy after neoadjuvant chemo-immunotherapy for triple-negative breast cancer and impact of the immunotherapy regimen.

2025 · Radiotherapy and Oncology · 0 citations

https://doi.org/10.1016/s0167-8140(25)01846-8

L Arranz Hernández Tamasine Khadrouche Mathilde Morisseau Amélie Lusque

Bone marrow 18F-FDG PET/CT metabolic activity: a surrogate marker for inflammation tumor load in patients with advanced ovarian cancer.

2026 · International Journal of Gynecological Cancer · 0 citations

https://doi.org/10.1016/j.ijgc.2025.103904

Anne-Sophie Navarro Mathieu Sinigaglia Mathilde Morisseau Charlotte Chollet

Abstract PD3-08: Evidence Accumulates Against Sequencing Topo1-ADCs in HER2-Low Metastatic Breast Cancers: results from International, retrospective, real-world ADC-Low-Europe cohort

2026 · Clinical Cancer Research · 0 citations

https://doi.org/10.1158/1557-3265.sabcs25-pd3-08

F. Poumeaud Mathilde Morisseau Sarah Cavaillon

Research topics

topics

Cancer Immunotherapy and Biomarkers

HER2/EGFR in Cancer Research

Cancer Treatment and Pharmacology

Head and Neck Cancer Studies

Immunotherapy and Immune Responses

Chat about Author

Papers

Chat

Click to start Chat